Filing Flows › Amneal Pharmaceuticals (AMRX) › Q2 2025
Amneal Pharmaceuticals (AMRX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Amneal Pharmaceuticals (AMRX) reported revenue of $725M for the second quarter 2025 (Q2 2025), +3% from a year earlier and +4% from the quarter before. Operating margin was 15.4%, net earnings $22.4M (3.1% of revenue).
Amneal Pharmaceuticals, Q2 2025: revenue $725M (+3% year over year), operating margin 15.4%, net earnings $22.4M, operating cash flow $83.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $725M | +4% | +3% |
| Gross profit | $286M | +12% | +15% |
| Operating profit | $111M | +11% | +17% |
| Net earnings | $22.4M | +84% | +274% |
| Operating cash flow | $83.8M | 11× | +111% |
| Free cash flow | $61.0M | — | +110% |
What changed
Revenue was $724.5M in Q2 2025, up 3% year over year and up 4% from the previous quarter.
Gross margin was 39.5%, up 3.9 points from a year earlier. Operating profit was $111.4M, a 15.4% margin (up 1.8 points year over year). Of the extra revenue versus a year earlier, 70% reached operating profit, above the 14% margin then. Operating expenses grew 13% against revenue growth of 3%. The fastest-growing cost line was Other operating costs (+35%). Net earnings were $22.4M, up 274% year over year. The effective tax rate was 31.1%.
Operating cash flow was $83.8M (up 111% year over year), 235% of net income including minority interests. Non-cash charges added back $8.3M of share-based compensation. Working capital and other items added $39.9M. Capital expenditures of $22.8M left free cash flow of $61.0M.
Questions
What was Amneal Pharmaceuticals' revenue in the second quarter 2025?
Amneal Pharmaceuticals (AMRX) reported revenue of $725M for the second quarter 2025 (Q2 2025), +3% from a year earlier and +4% from the quarter before.
Was Amneal Pharmaceuticals profitable in the second quarter 2025?
Operating profit was $111M (15.4% of revenue) and net earnings $22.4M.